Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE versus THORAZINE.
FLUPHENAZINE vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with high potency and additional antagonism at alpha-adrenergic, muscarinic, and histaminergic receptors.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Fluphenazine decanoate (long-acting): 12.5-25 mg IM every 2 weeks; Fluphenazine hydrochloride (oral): 2.5-10 mg daily in divided doses; initial titration 2.5-10 mg/day, maintenance 1-5 mg/day. Maximum oral dose 20 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Clinical Note
moderateFluphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone propionate."
Clinical Note
moderateFluphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Fluphenazine."
Clinical Note
moderateFluphenazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life is 15-30 hours, but may extend to 40-50 hours after chronic use; clinical context: dosing interval is typically 12-24 hours, and steady-state is reached within 3-5 days.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Primarily hepatic metabolism with biliary excretion. Less than 1% excreted unchanged in urine; fecal elimination accounts for approximately 20-30% of metabolites.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
Fluphenazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine."